SCHEMBL6323841

SCHEMBL6323841

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4cccc(F)c4)c32)c(C)c1CC(=O)NCCN1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 10/20 0.57
KDR P35968 10/20 0.57
FGFR1 P11362 5/20 0.57
TLK2 Q86UE8 2/20 0.57
KIT P10721 3/20 0.46
CSF1R P07333 2/20 0.46
FLT1 P17948 2/20 0.46
LCK P06239 2/20 0.46
KCNH2 Q12809 2/20 0.46
CHEK1 O14757 2/20 0.46
ALK Q9UM73 2/20 0.46
ABL1 P00519 1/20 0.46
FYN P06241 1/20 0.46
RET P07949 1/20 0.46
PHKG2 P15735 1/20 0.46
FGFR3 P22607 1/20 0.46
AXL P30530 1/20 0.46
ABL2 P42684 1/20 0.46
PTK2 Q05397 1/20 0.46
PTK2B Q14289 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6327103 0.94 KDR (0.58) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6321750 0.89 KDR (0.53) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6321236 0.88 PDGFRB (0.51) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6320259 0.88 KDR (0.52) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6321745 0.85 KDR (0.59) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6327668 0.84 PDGFRB (0.48) PDGFRBKDRFGFR1TLK2CSF1R
SCHEMBL6328657 0.84 PDGFRB (0.46) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6321746 0.83 KDR (0.55) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6327771 0.81 KDR (0.44) PDGFRBKDRFGFR1TLK2KIT
SCHEMBL6319633 0.81 KDR (0.52) PDGFRBKDRFGFR1TLK2KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 PDGFRB 575/4885KDR 819/4885FGFR1 525/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 PDGFRB 575/4885KDR 819/4885FGFR1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.